CRBU
Caribou Biosciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 3
Consensus Rating "Strong Buy"
MACD Golden Cross
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Price Hits New Low
Price Hits 52-week Low
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CRBU
Caribou Biosciences, Inc.
A clinical-stage biopharmaceutical company that develops gene-editing cell therapies
2929 7th Street, Suite 105, Berkeley, California 94710
--
Caribou Biosciences, Inc., was incorporated in Delaware in October 2011. The company is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying the company's new CRISPR platform, CRISPR hybrid RNA-DNA or chRDNA to develop next-generation genome editing cell therapies.
Company Financials
EPS
CRBU has released its 2025 Q3 earnings. EPS was reported at -0.3, versus the expected -0.36, beating expectations. The chart below visualizes how CRBU has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CRBU has released its 2025 Q3 earnings report, with revenue of 2.20M, reflecting a YoY change of 8.60%, and net profit of -27.55M, showing a YoY change of 20.57%. The Sankey diagram below clearly presents CRBU's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
